clinical trial · NCT03359889
PraxbindTM India PMS Program
Boehringer Ingelheim·—·completed·n = 5
ThromboembolismPraxbindTM
brief summary
This program will be initiated after the commercial availability of PraxbindTM in India. It will include patients administered with PraxbindTM into the surveillance program after commercial availability in 2 years at selected centres approved by the regulatory authority.
started
Dec 26, 2018
primary completion
Jan 13, 2020
completion
Jan 13, 2020
last updated
Aug 25, 2023
official title
Post Marketing Surveillance Program of Praxbind Use in India.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol